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Abstract: Poly(N-vinyl pyrrolidone) (PVP), poly(2-methyl-2-oxazoline) (PMOZ), poly(2-ethyl-2-
oxazoline) (PEOZ), poly(2-n-propyl-2-oxazoline) (PnPOZ), and poly(2-isopropyl-2-oxazoline) (PiPOZ)
were used to prepare solid dispersions with ibuprofen (IB), a model poorly-water soluble drug. Dis-
persions, prepared by solvent evaporation, were investigated using powder X-ray diffractometry,
differential scanning calorimetry, and FTIR spectroscopy; hydrogen bonds formed between IB and all
polymers in solid dispersions. PMOZ, the most hydrophilic polymer, showed the poorest ability to
reduce or inhibit the crystallinity of IB. In contrast, the more hydrophobic polymers PVP, PEOZ, Pn-
POZ, and PiPOZ provided greater but similar abilities to reduce IB crystallinity, despite the differing
polymer hydrophobicity and that PiPOZ is semi-crystalline. These results indicate that crystallinity
disruption is predominantly due to hydrogen bonding between the drug molecules and the polymer.
However, carrier properties affected drug dissolution, where PnPOZ exhibited lower critical solution
temperature that inhibited the release of IB, whereas drug release from other systems was consistent
with the degree of ibuprofen crystallinity within the dispersions.
Keywords: solid dispersions; hydrogen bonding; hydrophobicity; poly(N-vinyl pyrrolidone); poly(2-
oxazolines); crystallinity; hydrophobic drug; amorphous; ibuprofen
1. Introduction
Whilst oral delivery remains the most common route for drug administration, most
new active pharmaceutical ingredients are poorly water soluble and thus not well-absorbed
after oral administration. Solid dispersion, defined as the dispersion of one or more active
ingredient in a carrier or matrix at solid state, is an established platform technology to
enhance the dissolution rate and improve the apparent solubility of a drug and, hence,
increase the bioavailability of a range of poorly water soluble drugs [1–3]. Several classes
of hydrophilic polymers have been used as carriers to prepare solid dispersions, including
PVP [4–6] and its derivatives [7–9], polyethylene glycols [10,11], cellulose ethers [12,13]
and poloxamers [14,15].
In solid dispersions, polymer–drug interactions can provide stability to the system by
restricting the mobility of the drug molecules in the polymer matrix. Common interactions
between drugs and polymers include ionic, hydrophobic, dipole–dipole, Van der Waals,
and hydrogen bonding [16–18]. Hydrogen bonding is typically detected between drugs
and polymers in solid dispersions, as reported extensively, for example, between IB and
PVP [19,20], esomeprazole and hydroxypropyl methylcellulose (HPMC) [21], flurbiprofen
and poly(ethylene oxide) [22], and for nifedipine and Eudragit® [23], indicating that this
is a key mechanism in the successful formation of amorphous or semi-crystalline solid
dispersions. In contrast, there are relatively few studies exploring the effects of carrier
hydrophobicity on crystallization inhibition [16,24,25]. However, research typically focuses
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on hydrogen bonding or hydrophobicity, with little consideration given to the mutual
effects of hydrogen bonding and polymer hydrophobicity on drug crystal inhibition.
Poly(2-oxazolines) have been reported as an alternative to PVP in solid dispersions for
solubility and dissolution rate enhancement of poorly-water soluble drugs. For example,
Fael et al. [26] found that a lower molecular weight of PEOZ (5000 g/mol) was superior
to a higher molecular weight of the polymer (50,000 g/mol) in improving the dissolution
behavior of glipizide. Boel et al. [27] showed that PEOZ maintained supersaturation of
itraconazole and fenofibrate to a similar extent as PVP, poly(vinylpyrrolidone-co-vinyl
acetate) (PVP-VA), and HPMC. Everaerts et al. [28] selected PEOZ, PnPOZ, poly(2-sec-butyl-
2-oxazoline) (PsecBuOZ), and a combination of PEOZ with either PnPOZ or PsecBuOZ as
carriers for amorphous solid dispersions with six drugs, and highlighted the potential of
poly(2-oxazolines) as a novel polymer carrier to form amorphous solid dispersions.
In our previous work [29], PVP and a series of water-soluble poly(2-oxazolines)
including PMOZ, PEOZ, PnPOZ, and PiPOZ were used to prepare solid dispersions with
haloperidol. The effects of polymer hydrophobicity and their semi-crystalline nature on
drug crystallinity were demonstrated. However, hydrogen bonding between haloperidol
and poly(2-oxazolines) was almost absent due to the poor hydrogen bond donating ability
of the haloperidol hydroxyl group.
In order to explore the impacts of both polymer hydrophobicity and drug–polymer hy-
drogen bonding, we selected IB, a hydrophobic crystalline drug and strong hydrogen bond
donor (because of its carboxylic group), to prepare solid dispersions with poly(2-oxazolines)
and PVP. Dispersions were prepared by solvent evaporation and characterized using FTIR
spectroscopy, differential scanning calorimetry, and powder X-ray diffractometry. Solu-
bility parameters and Flory–Huggins interaction parameters were calculated to predict
drug–polymer miscibility, and drug dissolution studies were conducted to further explore
the relationship between IB crystallization inhibition and release from the dispersions.
2. Materials and Methods
2.1. Materials
Poly(2-ethyl-2-oxazoline) (PEOZ), 50 kDa (polydispersity index, PDI 3-4); poly(N-
vinyl pyrrolidone) (PVP), 55 kDa (K-value 30); and buffer tablets, pH 6.8 were from
Sigma-Aldrich (Gillingham, UK). Poly(2-methyl-2-oxazoline) (PMOZ), poly(2-n-propyl-2-
oxazoline) (PnPOZ), and poly(2-isopropyl-2-oxazoline) (PiPOZ) were synthesized accord-
ing to our previously reported procedure [29]. Ibuprofen (IB) was from Tokyo Chemistry
Industry (Japan). N, N-dimethylacetamide (DMA) was from Fisher Scientific (Loughbor-
ough, UK).
2.2. Preparation of Polymer–IB Solid Dispersions
Solid dispersions of polymer–IB were prepared in different repeating unit/drug
molar ratios by solvent evaporation. DMA (1 mL) was used to dissolve 25 mg of IB with
varying amounts of each polymer depending on the repeating unit/drug molar ratios. After
dissolution, the solution was transferred to a Petri dish and the solvent was removed by
evaporation at 50 ◦C on a heating base. The resultant solid was kept under vacuum for
72–96 h to remove residual DMA.
2.3. Characterization of Solid Dispersions
2.3.1. Powder X-ray Diffractometry (PXRD)
A small amount of each dry sample (~20 mg) was placed on a silica plate and analyzed
in a Bruker D8 ADVANCE PXRD using Cu Kα radiation (λ = 1.5406 Å) over 5–64◦ for 1 h,
with a step of 0.05◦(2θ) and count time of 1.2 s at 40 mV, 40 mA, with the sample rotated
at 30 rpm. The results were analyzed using EVA software and the background for each
sample was removed.
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2.3.2. Differential Scanning Calorimetry (DSC)
Thermal analysis of pure drug, polymers, and solid dispersions was performed
using DSC (TA Instruments). Samples (3–5 mg) were loaded into pierced Tzero aluminum
pans. The thermal behavior of each sample was investigated in a nitrogen atmosphere
from 10 to a maximum of 220 ◦C at 10 ◦C/min. The degree of sample crystallinity was
determined by the specific enthalpy (∆H) of the drug melting peak using TA universal
analysis software and was calculated as the ratio of ∆H of the drug in the solid dispersions
to ∆H of pure IB (taken as 100% crystalline). Since the drug content in the dispersion was
only a fraction of the sample weight, the degree of crystallinity was normalized according







/∆Hi × 100 (1)
where ∆Hs is the ∆H of the drug in the solid dispersion, melting around 76 ◦C (melting
point of IB), ∆Hi is the ∆H of pure IB, Ws is the weight of solid dispersions, and Wi is the
weight of IB in solid dispersions.
2.3.3. Fourier Transform Infrared (FTIR) Spectroscopy
FTIR spectra were recorded on a Nicolet iS5 spectrometer using a diamond ATR
(attenuated total reflection) accessory. After a background scan was collected, samples were
placed on the crystal and scanned from 4000–400 cm−1 at a resolution of 4 cm−1 and with
an average of 64 scans. OMINIC software was used for spectral analysis.
2.4. In Vitro Dissolution Studies
Dissolution of IB from solid dispersions ([polymer repeat unit]/[drug] = 1:1 mol/mol)
used USP Apparatus II (paddle method) at 37 ± 0.5 ◦C with paddles at 50 rpm and
simulated intestinal fluid (SIF) (PBS, pH = 6.8). A pharmaceutical grade empty vegan clear
capsule size “0” filled with solid dispersion (equivalent to 100 mg drug) was placed in
900 mL SIF with a sinker. Samples (5 mL) were withdrawn at 2, 5, 10, 20, 40, 60, 80, 100,
and 120 min, and filtered using a 0.45-µm syringe filter; an equal volume of SIF was added
to the dissolution medium to maintain the volume. The drug was assayed by UV-visible
spectroscopy at 265 nm. All dissolution studies were performed in triplicate.
2.5. Statistical Analysis
All solid dispersions for each polymer at all drug loadings were prepared three times
independently. All analyses, PXRD, DSC, FTIR, and dissolution studies were in triplicate.
Data are expressed as mean ± standard deviation.
3. Results and Discussion
3.1. Preparation and Characterization of Solid Dispersions
To evaluate the effects of different polymers on the crystallinity of IB, solid dispersions
were prepared by solvent evaporation and were characterized by DSC, PXRD, and FTIR,
with DSC used to calculate the crystallinity of IB in the dispersions. The X-ray diffractogram
of IB (Figure 1) shows multiple distinctive peaks, notably at 6.2◦, 12.3◦, 14.1◦, 14.9◦, 16.8◦,
17.9◦, 19.6◦, 20.3◦, 22.5◦, 25.3◦, 28.4◦, and 28.8◦, in agreement with the literature [30] and
demonstrating the crystalline nature of pure IB.
Clearly, the drug is diluted when included in the polymer dispersion, and so peak
intensities fall in all solid dispersions with PVP, PEOZ, PnPOZ, and PiPOZ at molar ratio
[polymer]/[IB] = 0.3:1. In these systems, the drug is in excess of the polymer hydrogen
bond acceptor repeat units and so is expected to remain largely crystalline. However, when
the molar ratio of polymer repeat unit to IB is 1:1, the X-ray data in Figure 1 indicate that IB
crystallinity is completely lost (although PMOZ systems showed some anomalous results,
discussed below). It is also interesting to note that PiPOZ alone is semi-crystalline and
presents a feature at 8.14◦ 2θ, but this is lost at both 0.3:1 (where IB is in excess) and at
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a 1:1 mole ratio with the drug (highlighted in Figure 1d). This demonstrates that whilst
solid dispersion studies typically focus on disruption of drug crystallinity, clearly the
interactions between drug and carrier can also affect the nature and properties of the
polymeric dispersant.
Figure 1. Cont.
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Figure 1. X-ray diffraction diagrams of PVP-IB SDs (a), PEOZ-IB SDs (b), PnPOZ-IB SDs (c), PiPOZ-IB
SDs (d), and PMOZ-IB SDs (e).
When dispersed in PMOZ, the X-ray data indicate different behavior for ibuprofen. As
above, at a 0.3:1 molar ratio, where the drug is in excess, there is a reduction in the intensity
of the peaks from ibuprofen due to the dilution effect. Some peaks observed in samples at
this ratio were slightly shifted from their positions seen with pure ibuprofen at 19.6◦, 20.3◦,
and 22.5◦ (denoted as 4, 5, and 6, respectively, in Figure 1e) while the characteristic peak
of IB at 16.8◦ 2θ did not significantly move, indicating that IB was predominantly in its
original form. However, in contrast with the other polymers, it is clear that ibuprofen has
some structure in PMOZ at 1:1, 1:2, and 1:5 drug:polymer compositions, with a series of
broader diffraction features seen between 16 and 20◦; again, these features show reduced
intensities as the drug is further diluted in the polymer. For these systems, the original
strong diffraction peak from the initial crystalline ibuprofen at 16.8◦ 2θ is lost, and broader
features at 16.1◦, 17.2◦, and 19.5◦ 2θ are seen (peaks 2, 3, and 4, respectively, in Figure 1e).
Further, a new feature at 10.5◦ is seen in these systems, which is absent from the pure
ibuprofen diffractogram (peak 1). The changes to the diffraction peak positions and breadth
of the new features are consistent with a semi-crystalline structure, but one that differs from
the initial ibuprofen crystal lattice. Racemic ibuprofen is known to be polymorphic, but the
diffraction peaks seen for the drug when dispersed in PMOZ are not consistent with the
reported form II polymorph [31]. Thus, in our system, it is feasible that a semi-crystalline
PMOZ-IB complex is formed. Finally, at a 1:10 drug:polymer composition, all diffraction
peaks were lost, suggesting the formation of an amorphous dispersion.
FTIR spectra were recorded from the components and dispersions to probe molec-
ular interactions. Functional groups of particular interest are the carboxyl group of IB
[−C=O(OH)], where the −OH acts as a proton donor, and the carbonyl group (–C=O) and
the nitrogen atom of polymers, which act as proton acceptors. In addition, correlation
between frequency shifts and intermolecular interaction between drugs and polymers in
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solid dispersions is well known [32–34], and so was used to investigate hydrogen bonding
in our polymer–drug solid dispersion systems.
The FTIR spectra of IB, polymers, and polymer–IB solid dispersions are shown in
Figures S1 and S2. For clarity, the spectra are expanded between 1800–1550 cm−1 in Figure 2.
IB vibrational frequencies and their assignments are given in Table S1 and agree with the
literature [35]. Briefly, absorption bands between 3100–2800 cm−1 are attributed to C−H
stretching modes, with peak intensities gradually reducing as the drug quantity falls in the
solid dispersions (Figure S2). Two medium intensity features, appearing at 2725 cm−1 and
2633 cm−1 in the spectrum of IB, can be assigned to the stretching vibration of the cyclic
dimerized hydroxyl groups, which is subjected to intermolecular hydrogen bonding [19,36]
(Figure S1). However, these bands are lost in the spectra of amorphous solid dispersions,
indicating that the drug dimeric structure is lost as a result of interaction with the polymers.
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The FTIR spectrum of IB shows a strong carbonyl stretching mode at 1710 cm−1
(Figure 2), which shifted to higher wavenumbers when dispersed in the polymers, and
especially at ratios where X-ray diffraction showed no drug crystallinity (i.e., 1:1 ratios).
These red shifts are summarized in Table 1. In contrast to the polyoxazoline carriers, the
spectra of 0.3:1 mol PVP:IB showed that the IB carbonyl stretching mode shifted from
1710 cm−1 to 1727 cm−1, despite the excess of IB to polymer monomer units, indicating the
strong hydrogen bonding between IB with PVP may have consequential disruption to the
IB crystal lattice. Furthermore, the carbonyl stretching mode for PVP at 1654 cm−1 was
replaced by two peaks at 1634 cm−1 and 1673 cm−1, with this latter peak strengthening at
[PVP]/[IB] = 1:1 (Figure 2a).
Table 1. The red shift of the carbonyl stretching mode from the carboxylic acid of IB at 1710 cm−1 in
(polymer)/(IB) = 0.3 mol and 1:1 mol solid dispersions.
Polymer–Drug
Wavenumbers (cm−1)
0.3:1 mol Red Shift 1:1 mol Red Shift
PVP-IB 1727 17 1727 17
PMOZ-IB 1710 0 1713 3
PEOZ-IB 1711 1 1727 17
PnPOZ-IB 1713 3 1727 17
PiPOZ-IB 1712 2 1727 17
The 1:1 ratio of IB in dispersions with PEOZ, PnPOZ, and PiPOZ showed similar
infrared spectra, in agreement with that for PVP. The carbonyl stretching mode of IB
showed a consistent red shift of 17 cm−1 from 1710 cm−1 to 1727 cm−1, and the carbonyl
stretch in the polymers split from the single peak at 1626 or 1629 cm−1 to give features at
both higher and lower wavenumbers. At higher drug loadings (polymer: drug 0.3:1), the
data suggest some drug–polymer interactions occurred, but these are somewhat obscured
by the “free” excess IB within the systems.
As with the X-ray investigation, dispersions with PMOZ showed different molecular
interactions than for the other polyoxazolines. A modest red shift in the IB carbonyl feature
of 3 cm−1 was seen at a 1:1 stoichiometry, and when excess polymer was employed (10:1
polymer repeat unit: IB), the shift was still modest at 7 cm−1. The PMOZ carbonyl mode
was seen at 1621 cm−1 in the polymer alone (Figure 2e). There is again evidence for this
mode splitting in the dispersion with peaks consistently at ~1594 cm−1 and ~1650 cm−1 in
the samples at 0.3:1 and 1:1 mole ratios. This peak apparently moves towards ~1629 cm−1
as the polymer content increases, but in fact is due to the increased contribution of the
“excess” (or “free”) PMOZ carbonyl peak intensity, which overlaps and obscured the
carbonyl group of PMOZ that interacts with IB. The weaker interaction of PMOZ with
IB compared with that in other polyoxazoline dispersions can be attributed to PMOZ’s
relatively high hydrophilicity, which inhibits its ability to disorder the hydrophobic drug
molecules [29].
From the IR data, there is no evidence for hydrogen bonding between the carboxylic
groups of IB and nitrogen atoms in the polymers, given the invariant C-N stretching
mode (Figure S3). Although PVP can form hydrogen bonds either through the nitrogen
or carbonyl group [37], steric hindrance constrains the involvement of nitrogen atom
in intermolecular interactions, so the carbonyl group is more favorable for hydrogen
bonding [38,39].
Overall, the changes in the carbonyl band of IB and polymers indicate a modified
carbonyl environment caused by the hydrogen bonding between the carboxylic groups of
IB and carbonyl groups of the polymers. The relatively high red shift of the carbonyl mode
of IB at [PVP]/[IB] = 0.3:1 mol confirmed strong hydrogen bonding between the drug and
PVP, and at 1:1 mole ratio, the dispersions with PVP, PEOZ, PnPOZ, and PiPOZ all showed
similar red shifts of this feature, suggesting near equivalent hydrogen bond interaction
strengths. In contrast, the interaction between PMOZ and IB was relatively weak as a result
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of PMOZ’s high hydrophilicity, but no new spectral features were found to demonstrate
the presence of a novel drug: PMOZ complex.
DSC experiments were used to investigate the thermal behavior of the solid disper-
sions and to estimate drug crystallinity within the dispersions. The DSC thermogram of
pure IB showed a single characteristic melting peak at 76 ◦C, confirming its crystalline
nature (Figure 3) and in agreement with previous reports [40,41]. In all dispersions at 0.3:1
mole ratio, the excess IB was seen to melt at a lower temperature, and the broadening of
the melting event is consistent with disorder being introduced into the crystal lattice and
interactions with the polymer occurring. At 1:1 mole ratio, the drug melting peak was lost
in all dispersions except in dispersion with PMOZ, in agreement with the X-ray data.
With PMOZ, a second endothermic peak appeared at 121.2 ◦C in (PMOZ)/(IB) = 0.3:1,
at 137.7 ◦C in (PMOZ)/(IB) = 1:1, at 137.9 ◦C in (PMOZ)/(IB) = 2:1, and at 128.3 ◦C in
(PMOZ)/(IB) = 5:1, potentially due to semi-crystalline IB or a PMOZ-IB complex. In addi-
tion, the melting peak seen at 203.5 ◦C for semi-crystalline PiPOZ was lost in (PiPOZ)/(IB)
solid dispersions; whilst reports tend to focus on the disruption to drug crystallinity in
solid dispersions, clearly the drug also has the potential to disrupt the structure of the
polymeric carrier, as indicated here.
Drug crystallinity in polymer–IB solid dispersions was calculated from the specific
enthalpy of the melting peak. As can be seen from Figure 4, IB crystallinity was reduced
in all dispersions with PVP, PEOZ, PnPOZ, and PiPOZ, and the drug was essentially
amorphous at a molar ratio of 1:1. The crystallinity of IB in dispersions with PMOZ could
not be quantified by this approach due to the formation of new thermal features and the
potential formation of a complex with this polymer.
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Figure 3. DSC thermograms of PVP-IB SDs (a), PEOZ-IB SDs (b), PnPOZ-IB SDs (c), PiPOZ-IB SDs
(d), and PMOZ-IB SDs (e).
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Figure 4. Crystallinity of polymer–IB solid dispersions as a function of polymer molar fraction.
3.2. Theoretical Evaluation of Drug-Polymer Miscibility
3.2.1. Solubility Parameters
The solubility parameter is a measure of cohesive energy density (CED: the cohesive
energy per unit volume) of a material. The cohesive energy represents the total attractive
forces within a condensed state material and can be defined as the quantity of energy
needed to separate the atoms/molecules of a solid or liquid to a distance where the atoms
or molecules possess no potential energy, that is, no interactions occur between atoms
and molecules [30]. Consequently, solubility parameters have been used to predict the
solubility/miscibility of one component into/with another component [42]. For this study,
the solubility parameters were calculated using the Van Krevelen method [43], rather than



















where δ is the total solubility parameter; δd, the contribution from dispersion forces; δp,
the contribution from polar forces; δh, the contribution of hydrogen bonding; Fdi, the molar
attraction constant due to dispersion component; Fpi, the molar attraction constant due to
polar component; Ehi, the hydrogen bonding energy; and V, the molar volume. For various
groups, the values of Fdi, Fpi, Ehi, and V (molar volume) are given in the literature [43,45].
The solubility parameters of these five polymers were taken from our previous study [29]
and the solubility parameters calculated for IB and PVP are in good agreement with the
literature [46].
Compounds with similar values of δ are likely to be miscible because the energy
required to break interactions within each component is balanced by the energy released by
interaction between the components. Greenhalgh et al. [30] classified dispersions based on
the difference between the solubility parameters of excipients and drugs (∆δ). The authors
demonstrated that compounds with ∆δ < 7.0 MPa1/2 are likely to be miscible. However,
compounds with ∆δ > 10.0 MPa1/2 are likely to be immiscible. The calculated solubility
parameters for IB, PVP, PMOZ, PEOZ, PnPOZ, and PiPOZ are summarized in Table 2.
It can be seen from Table 2 that all the polymers are expected to be miscible with
IB with ∆δ values ranging from 3.1 to 6.9, except for PMOZ (∆δ = 7.6). The rank order
values for ∆δ miscibility (PiPOZ; PnPOZ; PEOZ; PVP) are inconsistent with their ability
to disrupt ibuprofen crystallinity, which may be explained by confounding factors such
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as the stronger hydrogen bonding seen between PVP and IB, as suggested from the FTIR
data (Table 1). Although widely used, this approach has limitations and tends to be most
widely applicable for drug–polymer systems where Van der Waals interactions play a
major role, whereas for drug–polymer mixtures forming highly directional interactions
such as hydrogen bonds or long range forces such as ionic interactions, this method can
yield erroneous results [1,47].
Table 2. Solubility parameters of drug and polymers.
Drug and Polymers
Solubility Parameters (δ) (MPa1/2)
Group Classification
Van Krevelen Method ∆δ
IB 19.4
PVP 26.3 6.9 Miscible
PMOZ 27.0 7.6 Not miscible
PEOZ 24.5 5.1 Miscible
PnPOZ 22.9 3.5 Miscible
PiPOZ 22.5 3.1 Miscible
3.2.2. Flory–Huggins Interaction Parameter
Flory–Huggins theory considers melting point depression as an indicator of miscibility.
According to this [48], the relationship between the melting temperature of the pure drug
(Tm0) and the depressed melting point of the drug in the drug–polymer system (Tm) can be













(1 − Φ) + χ(1 − Φ)2
)
(3)
where R is the gas constant (8.31 J/mol·K), ∆H is the heat of fusion of the pure drug, Φ
is the volume fraction of the drug in the solid dispersion (i.e., drug loading), m is the
volume ratio between polymer and drug, and χ is the drug–polymer interaction parameter
representing the difference between the drug–polymer contact interaction and the average
self-contact interactions of drug–drug and polymer–polymer [49]. A negative χ value
indicates that the interaction between a polymer and a drug is stronger than the attraction
within polymer–polymer and drug–drug pairs. More negative values of χ indicate better
affinity between the polymer and the drug and, for example, could be caused by hydrogen
bonding between the drug and the polymer. Positive χ values indicate that drug molecules
and polymer segments have stronger affinity to interact with those of their own kind rather
than interacting with each other [50].
Given that all the polymer–IB solid dispersion systems showed depressed drug melt-
ing points at (polymer)/(drug) = 0.3:1 mol, the χ values of these dispersions were calcu-
lated and are listed in Table 3. Again, the PMOZ-IB system could not be investigated by
this method.
Table 3. Flory–Huggins interaction parameters of polymer–IB solid dispersion systems at the molar ratio of 0.3:1.
Polymer–Drug










PEOZ-IB 74.1 37,050 189.51 73.80 −3.85
PnPOZ-IB 90.2 45,100 230.69 73.50 −3.32
PiPOZ-IB 90.5 45,250 231.46 73.34 −3.52
a is the molecular volume of polymer repeating unit, calculated from the literature [43,45]. b is the molecular volume of polymer, calculated
by multiplying Vpolymer repeat unit by the repeat unit number. c is the molecular volume of IB, calculated from the literature [43,45], and is in
agreement with the value taken from [52]. d is the volume ratio between the polymer and the drug.
As can be seen, the drug–polymer interaction parameters are all negative and broadly simi-
lar, ranging from −3.85 for PEOZ-IB to −3.32 for PnPOZ-IB. Interestingly, the Flory–Huggins ap-
proach suggests a rank order of (greatest interactions to least) of PEOZ > PVP > PiPOZ > PnPOZ,
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whereas the rank order of solubility parameter miscibility was PiPOZ > PnPOZ > PEOZ > PVP.
Clearly, both approaches provide approximations (almost a “yes/no” guide), rather than a
predictive ability to develop the optimal solid dispersion, since other factors influence the
polymer’s ability to disrupt the drug’s crystallinity.
The X-ray, thermal, and infrared studies showed that PMOZ has a lower propensity to
disorder ibuprofen than the other polymers. Its solubility parameter difference to ibuprofen
(∆δ) was 7.6 MPa1/2, and thus beyond the notional value of 7 for miscibility but close to the
borderline value 6.9 MPa1/2 calculated for PVP, which has the greatest tendency to disorder
the drug. An alternative explanation is that the hydrophobic–hydrophilic balance (HHB)
value for PMOZ (3.95) demonstrates that it is highly hydrophilic, and so the hydrophobic
IB molecules will be less likely to molecularly disperse into the hydrophilic domains of
PMOZ, consistent with our earlier findings on the non-hydrogen bonding dispersions with
haloperidol where, again, PMOZ showed reduced interactions compared with the more
hydrophobic carriers [29]. The importance of polymer hydrophobicity for crystal growth
inhibitors has previously been reported [16].
3.3. In Vitro Dissolution Studies
The dissolution profiles of IB and polymer–IB (all 1:1 mol/mol) solid disperisons are
shown in Figure 5. The dissolution of pure IB within 60 min was below 70%, with ~50%
released in the first 20 min. As expected from the crystallinity data (Figure 4), dissolution
was rapid from solid dispersions with PVP, PEOZ, and PiPOZ, where over 80% of the
drug was released in the first 20 min. Drug release from solid dispersion with PMOZ was
slower compared to PVP, PEOZ, and PiPOZ, but faster than IB alone, with ~70% of the
drug released in 20 min, consistent with the analytical and theoretical discussions above.
Despite the reduction of drug crystallinity and the system being essentially amorphous as
determined by XRD and DSC, dispersions formed with PnPOZ showed slower dissolution
than pure crystalline IB, with less than 30% released in 20 min. This result is consistent
with our previous study [29] and can be explained by this polymer’s lower critical solution
temperature (LCST) of ~25 ◦C [53,54], which is much lower than the temperature used
in the dissolution studies (37 ◦C). Under these conditions, PnPOZ remains insoluble in
the dissolution medium, which limits drug release from these solid dispersions. Further
detailed dissolution studies of these formulations will be of interest in the future, for
example, in assessing release below 25 ◦C and evaluating the extent of IB supersaturation
on the evolution of kinetic solubility profiles [55].
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4. Conclusions
Solid dispersions of IB were prepared using the poly(2-oxazolines) and PVP. Phys-
ical characterization of the dispersions showed that the polymers were able to disrupt
the ibuprofen crystallinity, forming apparently amorphous dispersion at 1:1 mole ratios,
and that hydrogen bonding was the prime mechanism for the interaction; however, the
interactions between PMOZ and ibuprofen were more complex and hydrogen bonding
was less prominent. The theoretical approach using the differences in solubility parameters
between the drug and carrier or calculating the Flory–Huggins interaction parameters
suggested compatibility between the drug and carriers, but the rank order of the predicted
interactions varied between the two approaches. The purpose of generating solid disper-
sions is to enhance the dissolution rate of a poorly water soluble drug, and our studies
demonstrated that the dispersions were able to significantly increase ibuprofen dissolution.
However, our studies also show that other factors can significantly impact the performance
of a solid dispersion. Physical characterization, for example, XRD showing that the drug
is amorphous, can be assumed to result in enhanced dissolution. However, we show that
not only is the crystallinity of a drug affected by dispersion, but so too is the structure of a
semi-crystalline polymer (PiPOZ). The hydrophilicity of a carrier may reduce interactions
with a hydrophobic drug, and so HHB may be an additional factor. Furthermore, the solu-
tion behavior of the carrier can also influence performance; physical characterization and
theoretical models implied that dispersions with PnPOZ would be as effective as the other
carriers, but the lower critical solution temperature (~25 ◦C) meant that this amorphous
dispersion performed worse than the ibuprofen alone in the dissolution studies. Thus,
both physical interactions, such as hydrogen bonding, and polymer properties, such as
hydrophobicity, need to be considered when selecting carriers for solid dispersions.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/pharmaceutics13050659/s1, Figure S1. FTIR of ibuprofen. Figure S2: FTIR full spectra of PVP-
IB SDs (a), PEOZ-IB SDs (b), PnPOZ-IB SDs (c), PiPOZ-IB SDs (d) and PMOZ-IB SDs (e) Figure S3:
FTIR spectra of PVP-IB SDs and POZ-IB SDs in the range of 1400~900 cm−1. The peaks (marked
with an arrow) are attributed to C-N mode. Table S1: FTIR spectral data of ibuprofen (s—strong;
w—weak; sym—symmetrical; asym—asymmetrical; str—stretching; m—medium; vs—very strong;
vw—very weak.).
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